CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials designed to act on the gut-body network for the treatment of a wide range of diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. ET.

A live webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. An archived replay will be available for approximately 30 days following the presentation.

About Evelo Biosciences­Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing a new modality of medicine, monoclonal microbials, which are designed to act on the gut-body network. Evelo’s product candidates are orally-delivered, single strains of microbes, selected for their defined pharmacological properties. They are intended to modulate systemic immunology and biology by acting on multiple naturally evolved biological pathways through the gut-body network. Evelo believes that monoclonal microbials have the potential to be broadly applicable across many diseases including immunoinflammatory, cancer, autoimmune, metabolic, neurological and neuroinflammatory diseases.

Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer, for which ten clinical readouts are expected during 2019 and 2020. Evelo is also advancing additional candidates through preclinical development in other disease areas.

For more information, please visit www.evelobio.com.

Contact Evelo BiosciencesStefan Riley617-704-2333stefan@evelobio.com